WillItSurvive
Pharma and healthcare groups · India

Lupin Limited

lupin.com ↗

Lupin makes generic and specialty drugs, especially in the US and India, ranked #3 in US generics by prescriptions.

Protection under test
Assessed 26 July 2026 · Evidence as of 26 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 26 July 2026 · Checkable from Aug 2026 · Every call on the record Checkpoint: US tariff phase-in on pharma imports begins, hitting the 42% of revenue that comes from US sales
The call

Lupin is growing fast on US generics and a deep filing pipeline, but tariffs, FDA plant scrutiny, and guided margin compression are landing at the same time.

Lupin makes cheap, everyday medicines sold in the US and other countries. It is hard to replace quickly because the US Food and Drug Administration approves only certain manufacturers for each drug, and Lupin has hundreds of these approvals after years of regulatory work and factory inspections. But this business is brutal: prices fall constantly as competitors like Sun Pharma, Dr. Reddy's, and Teva battle for the same customers, and Lupin now faces US tariffs that could cut profits and a factory inspection that raised concerns. The one thing that could save the company is if its newer specialty medicines and cancer drugs (like Pegfilgrastim and drugs from its Kaveri unit) grow fast enough to replace the shrinking cash from generic pills.

Why
01
AI pressure: None apparent. Generic drug manufacturing and ANDA filing run on chemistry and regulatory filings, not AI, so no AI product is eating this business yet. Could AI do the core job? Unlikely.
02
Bigger players: Sun Pharma, Dr. Reddy's, Cipla, Aurobindo, Teva, Viatris, and Sandoz. These rivals sell overlapping generic molecules in the same US market, and price erosion on shared drugs like tolvaptan and mirabegron is ongoing. Could a giant copy it? Probably.
03
What protects it. 344 approved ANDAs, 52 First-to-File filings, and 15 FDA-audited plants make it hard for new entrants to just copy Lupin's US pipeline fast.
What would change this call
US implements full 200% pharma tariff without price relief after July 22, 2026 announcement. Would squeeze margins on the 42% of revenue tied to US sales.
Nagpur plant's 6 FDA observations (Sept 2025) escalate to a warning letter or import alert. Would signal weakening of the regulatory moat protecting US supply.
FY27 EBITDA margin comes in below the guided 25% level. Would confirm margin compression is outpacing management's own forecast.
Key numbers
  • FY2026 revenue ₹27,958 crore, up 23.1% YoY (2026-05-07)
  • US sales $1,318M, 42% of global revenue, up 46% YoY (2026-05-07)
  • FY27 EBITDA margin guided to ~25%, down from 29.7% (2026-05-09)
Named risks
  • US tariffs up to 200% on generic imports announced July 22, 2026, threatening 42% of revenue. Severity: high
  • FY27 EBITDA margin guided to fall to ~25% from 29.7% on tolvaptan and mirabegron generic erosion. Severity: medium
  • Nagpur plant received six USFDA observations in September 2025, response outcome undisclosed. Severity: medium
  • Ongoing patent litigation from Vertex Pharmaceuticals and Neurelis over ANDA products. Severity: medium
  • Ongoing Class II recall of 2.53 million contaminated eye-drop bottles since June 2026. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Sun Pharmaceuticallosing toSun Pharma posted ~₹13,851 crore quarterly revenue in Q1 FY26, roughly double Lupin's scale
Dr. Reddy's LaboratoriescontestingDr. Reddy's quarterly revenue ~₹8,572 crore vs Lupin, both chasing US ANDA exclusivities in 2026
Cipla Ltd.contestingCipla quarterly revenue ~₹6,957 crore, competing for same US generics niches as of Q1 FY26
Aurobindo PharmacontestingAurobindo's FY26 revenue ₹33,653 crore with 43% from US formulations, similar tariff exposure to Lupin's 42%
Questions people ask
Is Lupin Limited profitable in 2026?
Yes. Lupin's FY2026 (year ended March 31, 2026) consolidated revenue was ₹279,580 million, up 23.1% YoY, with profit after tax of ₹53,555 million, up 62.0% YoY, reported May 7, 2026.
Could AI replace Lupin's business?
No. Lupin's moat is FDA approvals, GMP manufacturing and legal exclusivity (52 First-to-Files as of March 2026). AI is used only for back-office tasks like SOP drafting and OOS analysis, per Lupin's own November 2025 statement.
Who owns Lupin Limited?
The Gupta family, via Lupin Investments Pvt. Ltd. and the Gupta Family Trust, held about 47.08% of shares (214,199,649 shares) as of the FY2023 SEBI disclosure, the most recent granular figure available; CEO is Vinita Gupta.
Is Sun Pharma Lupin's biggest competitor?
Sun Pharmaceutical is roughly double Lupin's scale, with about ₹13,851 crore quarterly revenue in Q1 FY26 versus Lupin's, alongside Dr. Reddy's, Cipla and Aurobindo, all contesting the same US ANDA and Indian generics markets.
What is Lupin's biggest current risk?
US tariffs. On July 22, 2026, the US President announced a phased plan for tariffs up to 200% on imported generic medicines, with an August 1, 2026 timeline component; Lupin's US business is 42% of its global revenue.
Did Lupin recall any products in 2026?
Yes. Lupin initiated a voluntary Class II FDA recall of about 2.53 million bottles of prednisolone acetate ophthalmic suspension made at its Pithampur, India plant on June 4, 2026, due to a foreign substance; the recall was still ongoing as of July 9, 2026.
Timeline
  • 2026-07-22US President announced phased tariff plan up to 200% on imported generics; Lupin has 42% US revenue exposure
  • 2026-07-21Lupin spun out PRMT5 and SOS1 oncology programs into new entity Kaveri Therapeutics
  • 2026-07-01Somerset, NJ facility received clean FDA EIR with satisfactory VAI classification
  • 2026-06-04Voluntary Class II recall of 2.53 million bottles of prednisolone acetate eye drops initiated
  • 2026-05-21US Federal Circuit affirmed Lupin's non-infringement win over Otsuka in tolvaptan case
  • 2026-05-09Q4 FY26 call cited 15th consecutive quarter of YoY growth; guided FY27 EBITDA margin near 25%
  • 2026-05-07FY2026 results: revenue ₹27,958 crore, PAT ₹5,355.5 crore, board recommended 900% dividend
  • 2025-12Lupin received its first biosimilar FDA approval, for Pegfilgrastim
  • 2025-09Lupin's Nagpur plant received six USFDA observations after inspection
  • 2025-08Lupin launched Glucagon Kit in the US, targeting a roughly $122 million market
Revision history
26 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
SolventumNovo NordiskBaxter International
More in Pharma and healthcare groups →
Sources